Genentech is developing an investigational sustained delivery device, called the Ranibizumab Port Delivery System (RPDS). The device could lower the burden of treatment for people with wet age-related macular degeneration who receive injections of Lucentis. Genentech recently initiated a Phase II study, called LADDER to assess the efficacy and safety of the implant.
Medical Director at Genentech in Ophthalmology Dr. Jill Hopkins joins us to discuss the RPDS implant and the LADDER study.